Drug safety in acute migraine treatment

Bibliography

• Edvinsson L, Villalon CM, MaassenVanDenBrink A. Basic mechanisms of migraine and its acute treatment. Pharmacol Ther 2012;136:319-33
   PubMed Web of Science ®Google Scholar
• Tajti J, Pardutz A, Vamos E, et al. Migraine is a neuronal disease. J Neural Transm 2011;118:511-24
   PubMed Web of Science ®Google Scholar
• Tajti J, Szok D, Pardutz A, et al. Where does a migraine attack originate? In the brainstem. J Neural Transm 2012;119:557-68
   PubMed Web of Science ®Google Scholar
• Tajti J, Csati A, Vecsei L. Novel strategies for the treatment of migraine attacks via the CGRP, serotonin, dopamine, PAC1, and NMDA receptors. Expert Opin Drug Metab Toxicol 2014;10:1509-20
   PubMed Web of Science ®Google Scholar
• Hood L, Flores M. A personal view on systems medicine and the emergence of proactive P4 medicine: predictive, preventive, personalized and participatory. N Biotechnol 2012;29:613-24
   PubMed Web of Science ®Google Scholar
• Tepper SJ, Millson D. Safety profile of the triptans. Expert Opin Drug Saf 2003;2:123-32
   PubMedGoogle Scholar
• Hug BL, Keohane C, Seger DL, et al. The costs of adverse drug events in community hospitals. Jt Comm J Qual Patient Saf 2012;38:120-6
   PubMedGoogle Scholar
• Gyllensten H, Hakkarainen KM, Hagg S, et al. Economic impact of adverse drug events--a retrospective population-based cohort study of 4970 adults. PLoS ONE 2014;9:e92061
   PubMed Web of Science ®Google Scholar
• Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine – revised report of an EFNS task force. Eur J Neurol 2009;16:968-81
   PubMed Web of Science ®Google Scholar
• Holland S, Silberstein SD, Freitag F, et al. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012;78:1346-53
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Holland S, Freitag F, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012;78:1337-45
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P, Block G, Dahlof C, et al. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia 2000;20:765-86
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Lipton RB, Ferrari MD. Migraine–current understanding and treatment. N Engl J Med 2002;346:257-70
   PubMed Web of Science ®Google Scholar
• Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;55:754-62
   PubMed Web of Science ®Google Scholar
• Da Silva AN, Tepper SJ. Acute treatment of migraines. CNS Drugs 2012;26:823-39
   PubMed Web of Science ®Google Scholar
• Maillard M, Burnier M. Comparative cardiovascular safety of traditional nonsteroidal anti-inflammatory drugs. Expert Opin Drug Saf 2006;5:83-94
   PubMed Web of Science ®Google Scholar
• Kitano A, Shimomura T, Takeshima T, Takahashi K. Increased 11-dehydrothromboxane B2 in migraine: platelet hyperfunction in patients with migraine during headache-free period. Headache 1994;34:515-18
   PubMed Web of Science ®Google Scholar
• Mezei Z, Kis B, Gecse A, et al. Platelet arachidonate cascade of migraineurs in the interictal phase. Platelets 2000;11:222-5
   PubMed Web of Science ®Google Scholar
• Sarchielli P, Alberti A, Coppola F, et al. Platelet-activating factor (PAF) in internal jugular venous blood of migraine without aura patients assessed during migraine attacks. Cephalalgia 2004;24:623-30
   PubMed Web of Science ®Google Scholar
• Borgdorff P, Tangelder GJ. Migraine: possible role of shear-induced platelet aggregation with serotonin release. Headache 2012;52:1298-318
   PubMed Web of Science ®Google Scholar
• Bigal ME, Kurth T, Santanello N, et al. Migraine and cardiovascular disease: a population-based study. Neurology 2010;74:628-35
   PubMed Web of Science ®Google Scholar
• Schurks M, Rist PM, Bigal ME, et al. Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ 2009;339:b3914
   PubMed Web of Science ®Google Scholar
• Kaube H, Hoskin KL, Goadsby PJ. Intravenous acetylsalicylic acid inhibits central trigeminal neurons in the dorsal horn of the upper cervical spinal cord in the cat. Headache 1993;33:541-4
   PubMed Web of Science ®Google Scholar
• Kroger IL, May A. Central effects of acetylsalicylic acid on trigeminal-nociceptive stimuli. J Headache Pain 2014;15:59
   PubMedGoogle Scholar
• Kirthi V, Derry S, Moore RA. Aspirin with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev 2013;4:CD008041
   PubMedGoogle Scholar
• Suthisisang CC, Poolsup N, Suksomboon N, et al. Meta-analysis of the efficacy and safety of naproxen sodium in the acute treatment of migraine. Headache 2010;50:808-18
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P, Olesen J. Effervescent metoclopramide and aspirin (Migravess) versus effervescent aspirin or placebo for migraine attacks: a double-blind study. Cephalalgia 1984;4:107-11
   PubMed Web of Science ®Google Scholar
• Warner TD, Giuliano F, Vojnovic I, et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 1999;96:7563-8
   PubMed Web of Science ®Google Scholar
• Voilley N, de Weille J, Mamet J, Lazdunski M. Nonsteroid anti-inflammatory drugs inhibit both the activity and the inflammation-induced expression of acid-sensing ion channels in nociceptors. J Neurosci 2001;21:8026-33
   PubMed Web of Science ®Google Scholar
• Bjorkman R. Central antinociceptive effects of non-steroidal anti-inflammatory drugs and paracetamol. Experimental studies in the rat. Acta Anaesthesiol Scand Suppl 1995;103:1-44
   PubMedGoogle Scholar
• Denuelle M, Fabre N, Payoux P, et al. Hypothalamic activation in spontaneous migraine attacks. Headache 2007;47:1418-26
   PubMed Web of Science ®Google Scholar
• Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. Nat Med 1995;1:658-60
   PubMed Web of Science ®Google Scholar
• Diener HC, Montagna P, Gacs G, et al. Efficacy and tolerability of diclofenac potassium sachets in migraine: a randomized, double-blind, cross-over study in comparison with diclofenac potassium tablets and placebo. Cephalalgia 2006;26:537-47
   PubMed Web of Science ®Google Scholar
• Lipton RB, Grosberg B, Singer RP, et al. Efficacy and tolerability of a new powdered formulation of diclofenac potassium for oral solution for the acute treatment of migraine: results from the International Migraine Pain Assessment Clinical Trial (IMPACT). Cephalalgia 2010;30:1336-45
   PubMed Web of Science ®Google Scholar
• Vecsei L, Gallacchi G, Sagi I, et al. Diclofenac epolamine is effective in the treatment of acute migraine attacks. A randomized, crossover, double blind, placebo-controlled, clinical study. Cephalalgia 2007;27:29-34
   PubMed Web of Science ®Google Scholar
• Garnock-Jones KP. Diclofenac potassium powder for oral solution: a review of its use in patients with acute migraine. CNS Drugs 2014;28:761-8
   PubMed Web of Science ®Google Scholar
• Derry S, Rabbie R, Moore RA. Diclofenac with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev 2013;4:CD008783
   PubMedGoogle Scholar
• Rainsford KD. Ibuprofen: pharmacology, efficacy and safety. Inflammopharmacology 2009;17:275-342
   PubMedGoogle Scholar
• Suthisisang C, Poolsup N, Kittikulsuth W, et al. Efficacy of low-dose ibuprofen in acute migraine treatment: systematic review and meta-analysis. Ann Pharmacother 2007;41:1782-91
   PubMed Web of Science ®Google Scholar
• Codispoti JR, Prior MJ, Fu M, et al. Efficacy of nonprescription doses of ibuprofen for treating migraine headache. a randomized controlled trial. Headache 2001;41:665-79
   PubMed Web of Science ®Google Scholar
• Davies NM, Anderson KE. Clinical pharmacokinetics of naproxen. Clin Pharmacokinet 1997;32:268-93
   PubMed Web of Science ®Google Scholar
• Hautaniemi T, Petrenko N, Skorinkin A, Giniatullin R. The inhibitory action of the antimigraine nonsteroidal anti-inflammatory drug naproxen on P2X3 receptor-mediated responses in rat trigeminal neurons. Neuroscience 2012;209:32-8
   PubMed Web of Science ®Google Scholar
• Levy D, Zhang XC, Jakubowski M, Burstein R. Sensitization of meningeal nociceptors: inhibition by naproxen. Eur J Neurosci 2008;27:917-22
   PubMed Web of Science ®Google Scholar
• Jakubowski M, Levy D, Kainz V, et al. Sensitization of central trigeminovascular neurons: blockade by intravenous naproxen infusion. Neuroscience 2007;148:573-83
   PubMed Web of Science ®Google Scholar
• Law S, Derry S, Moore RA. Naproxen with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev 2013;10:CD009455
   PubMedGoogle Scholar
• Anneken K, Evers S, Husstedt IW. Efficacy of fixed combinations of acetylsalicyclic acid, acetaminophen and caffeine in the treatment of idiopathic headache: a review. Eur J Neurol 2010;17:534-e25
   PubMed Web of Science ®Google Scholar
• Anderson BJ. Paracetamol (Acetaminophen): mechanisms of action. Paediatr Anaesth 2008;18:915-21
   PubMed Web of Science ®Google Scholar
• Prior MJ, Codispoti JR, Fu M. A randomized, placebo-controlled trial of acetaminophen for treatment of migraine headache. Headache 2010;50:819-33
   PubMed Web of Science ®Google Scholar
• Lecchi M, D’Alonzo L, Negro A, Martelletti P. Pharmacokinetics and safety of a new aspirin formulation for the acute treatment of primary headaches. Expert Opin Drug Metab Toxicol 2014;10:1381-95
   PubMed Web of Science ®Google Scholar
• Yeomans ND, Lanas AI, Talley NJ, et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 2005;22:795-801
   PubMed Web of Science ®Google Scholar
• Steiner TJ, Voelker M. Gastrointestinal tolerability of aspirin and the choice of over-the-counter analgesia for short-lasting acute pain. J Clin Pharm Ther 2009;34:177-86
   PubMed Web of Science ®Google Scholar
• Lampl C, Voelker M, Diener HC. Efficacy and safety of 1,000 mg effervescent aspirin: individual patient data meta-analysis of three trials in migraine headache and migraine accompanying symptoms. J Neurol 2007;254:705-12
   PubMed Web of Science ®Google Scholar
• MacGregor EA, Dowson A, Davies PT. Mouth-dispersible aspirin in the treatment of migraine: a placebo-controlled study. Headache 2002;42:249-55
   PubMed Web of Science ®Google Scholar
• Rabbie R, Derry S, Moore RA. Ibuprofen with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev 2013;4:CD008039
   PubMedGoogle Scholar
• Smith TR, Sunshine A, Stark SR, et al. Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache 2005;45:983-91
   PubMed Web of Science ®Google Scholar
• Jozwiak-Bebenista M, Nowak JZ. Paracetamol: mechanism of action, applications and safety concern. Acta Pol Pharm 2014;71:11-23
   PubMed Web of Science ®Google Scholar
• Derry S, Moore RA. Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev 2013;4:CD008040
   PubMedGoogle Scholar
• Diener HC, Pfaffenrath V, Pageler L, et al. The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination for the treatment of headache: a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia 2005;25:776-87
   PubMed Web of Science ®Google Scholar
• Goldstein J, Silberstein SD, Saper JR, et al. Acetaminophen, aspirin, and caffeine in combination versus ibuprofen for acute migraine: results from a multicenter, double-blind, randomized, parallel-group, single-dose, placebo-controlled study. Headache 2006;46:444-53
   PubMed Web of Science ®Google Scholar
• Goldstein J, Gawel MJ, Winner P, et al. Comparison of butorphanol nasal spray and fiorinal with codeine in the treatment of migraine. Headache 1998;38:516-22
   PubMed Web of Science ®Google Scholar
• Loder E. Fixed drug combinations for the acute treatment of migraine : place in therapy. CNS Drugs 2005;19:769-84
   PubMed Web of Science ®Google Scholar
• Straube A, Aicher B, Fiebich BL, Haag G. Combined analgesics in (headache) pain therapy: shotgun approach or precise multi-target therapeutics? BMC Neurol 2011;11:43
   PubMedGoogle Scholar
• Goldstein J, Silberstein SD, Saper JR, et al. Acetaminophen, aspirin, and caffeine versus sumatriptan succinate in the early treatment of migraine: results from the ASSET trial. Headache 2005;45:973-82
   PubMed Web of Science ®Google Scholar
• Bach PH, Berndt WO, Delzell E, et al. A safety assessment of fixed combinations of acetaminophen and acetylsalicylic acid, coformulated with caffeine. Ren Fail 1998;20:749-62
   PubMed Web of Science ®Google Scholar
• Harrington RA, Hamilton CW, Brogden RN, et al. Metoclopramide. An updated review of its pharmacological properties and clinical use. Drugs 1983;25:451-94
   PubMed Web of Science ®Google Scholar
• Ganzini L, Casey DE, Hoffman WF, McCall AL. The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Arch Intern Med 1993;153:1469-75
   PubMed Web of Science ®Google Scholar
• Miller LG, Jankovic J. Metoclopramide-induced movement disorders. Clinical findings with a review of the literature. Arch Intern Med 1989;149:2486-92
   PubMed Web of Science ®Google Scholar
• Grimes JD, Hassan MN, Preston DN. Adverse neurologic effects of metoclopramide. Can Med Assoc J 1982;126:23-5
   PubMed Web of Science ®Google Scholar
• Rumore MM, Lee SE, Wang S, Farmer B. Metoclopramide-induced cardiac arrest. Clin Pract 2011;1:e83
   Google Scholar
• Champion MC, Hartnett M, Yen M. Domperidone, a new dopamine antagonist. CMAJ 1986;135:457-61
   PubMed Web of Science ®Google Scholar
• Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-8; 2 p following 28
   PubMed Web of Science ®Google Scholar
• Coxib, traditional NTC. Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013;382:769-79
   PubMed Web of Science ®Google Scholar
• Bello AE, Holt RJ. Cardiovascular risk with non-steroidal anti-inflammatory drugs: clinical implications. Drug Saf 2014;37:897-902
   PubMed Web of Science ®Google Scholar
• Salvo F, Antoniazzi S, Duong M, et al. Cardiovascular events associated with the long-term use of NSAIDs: a review of randomized controlled trials and observational studies. Expert Opin Drug Saf 2014;13:573-85
   PubMed Web of Science ®Google Scholar
• Moore N, Salvo F, Duong M, et al. Cardiovascular risks associated with low-dose ibuprofen and diclofenac as used OTC. Expert Opin Drug Saf 2014;13:167-79
   PubMed Web of Science ®Google Scholar
• Belvis R, Mas N, Aceituno A. Migraine attack treatment : a tailor-made suit, not one size fits all. Recent Pat CNS Drug Discov 2014;9:26-40
   PubMedGoogle Scholar
• Katic BJ, Golden W, Cady RK, Hu XH. GERD prevalence in migraine patients and the implication for acute migraine treatment. J Headache Pain 2009;10:35-43
   PubMed Web of Science ®Google Scholar
• Sostres C, Gargallo CJ, Arroyo MT, Lanas A. Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res Clin Gastroenterol 2010;24:121-32
   PubMed Web of Science ®Google Scholar
• Sostres C, Gargallo CJ, Lanas A. Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Res Ther 2013;15(Suppl 3):S3
   PubMed Web of Science ®Google Scholar
• Saper JR, Silberstein S. Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine. Headache 2006;46(Suppl 4):S171-81
   PubMed Web of Science ®Google Scholar
• Markowitz S, Saito K, Moskowitz MA. Neurogenically mediated plasma extravasation in dura mater: effect of ergot alkaloids. A possible mechanism of action in vascular headache. Cephalalgia 1988;8:83-91
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Gundlach AL. Localization of 3H-dihydroergotamine-binding sites in the cat central nervous system: relevance to migraine. Ann Neurol 1991;29:91-4
   PubMed Web of Science ®Google Scholar
• Tepper SJ. Orally inhaled dihydroergotamine: a review. Headache 2013;53(Suppl 2):43-53
   PubMedGoogle Scholar
• Silberstein SD, Kori SH. Dihydroergotamine: a review of formulation approaches for the acute treatment of migraine. CNS Drugs 2013;27:385-94
   PubMed Web of Science ®Google Scholar
• Callaham M, Raskin N. A controlled study of dihydroergotamine in the treatment of acute migraine headache. Headache 1986;26:168-71
   PubMed Web of Science ®Google Scholar
• Graham JR, Wolff HG. Mechanism of migraine headache and action of ergotamine tartrate. Arch Neurol Psychiatry 1938;39:737-63
   Google Scholar
• Roberto G, Raschi E, Piccinni C, et al. Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: systematic review of observational studies. Cephalalgia 2015;35(2):118-31
   PubMed Web of Science ®Google Scholar
• Kurth T, Schurks M, Logroscino G, et al. Migraine, vascular risk, and cardiovascular events in women: prospective cohort study. BMJ 2008;337:a636
   PubMed Web of Science ®Google Scholar
• MacClellan LR, Giles W, Cole J, et al. Probable migraine with visual aura and risk of ischemic stroke: the stroke prevention in young women study. Stroke 2007;38:2438-45
   PubMed Web of Science ®Google Scholar
• Dobson CF, Tohyama Y, Diksic M, Hamel E. Effects of acute or chronic administration of anti-migraine drugs sumatriptan and zolmitriptan on serotonin synthesis in the rat brain. Cephalalgia 2004;24:2-11
   PubMed Web of Science ®Google Scholar
• Derry CJ, Derry S, Moore RA. Sumatriptan (all routes of administration) for acute migraine attacks in adults - overview of Cochrane reviews. Cochrane Database Syst Rev 2014;5:CD009108
   PubMed Web of Science ®Google Scholar
• Patten JP. Clinical experience with oral sumatriptan: a placebo-controlled, dose-ranging study. Oral Sumatriptan Dose-defining Study Group. J Neurol 1991;238(Suppl 1):S62-5
   PubMedGoogle Scholar
• Vikelis M, Mitsikostas DD, Rapoport AM. Sumatriptan transdermal iontophoretic patch (NP101-Zelrix): review of pharmacology, clinical efficacy, and safety in the acute treatment of migraine. Neuropsychiatr Dis Treat 2012;8:429-34
   PubMed Web of Science ®Google Scholar
• Vikelis M, Mitsikostas DD, Rapoport AM. Sumatriptan iontophoretic transdermal system for the acute treatment of migraine. Pain Manag 2014;4:123-8
   Google Scholar
• Knyihar-Csillik E, Tajti J, Csillik AE, et al. Effects of eletriptan on the peptidergic innervation of the cerebral dura mater and trigeminal ganglion, and on the expression of c-fos and c-jun in the trigeminal complex of the rat in an experimental migraine model. Eur J Neurosci 2000;12:3991-4002
   PubMed Web of Science ®Google Scholar
• Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001;358:1668-75
   PubMed Web of Science ®Google Scholar
• Milton KA, Scott NR, Allen MJ, et al. Pharmacokinetics, pharmacodynamics, and safety of the 5-HT(1B/1D) agonist eletriptan following intravenous and oral administration. J Clin Pharmacol 2002;42:528-39
   PubMed Web of Science ®Google Scholar
• Katsarava Z, Limmroth V, Baykal O, et al. Differences of anti-nociceptive mechanisms of migraine drugs on the trigeminal pain processing during and outside acute migraine attacks. Cephalalgia 2004;24:657-62
   PubMed Web of Science ®Google Scholar
• Lionetto L, Casolla B, Mastropietri F, et al. Pharmacokinetic evaluation of zolmitriptan for the treatment of migraines. Expert Opin Drug Metab Toxicol 2012;8:1043-50
   PubMed Web of Science ®Google Scholar
• Rapoport AM, Ramadan NM, Adelman JU, et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group. Neurology 1997;49:1210-18
   PubMed Web of Science ®Google Scholar
• Bird S, Derry S, Moore RA. Zolmitriptan for acute migraine attacks in adults. Cochrane Database Syst Rev 2014;5:CD008616
   PubMedGoogle Scholar
• Wang X, Yu S, Dong Z, Jiang L. The Fos expression in rat brain following electrical stimulation of dura mater surrounding the superior sagittal sinus changed with the pre-treatment of rizatriptan benzoate. Brain Res 2011;1367:340-6
   PubMed Web of Science ®Google Scholar
• Pascual J. A review of rizatriptan, a quick and consistent 5-HT1B/1D agonist for the acute treatment of migraine. Expert Opin Pharmacother 2004;5:669-77
   PubMed Web of Science ®Google Scholar
• Block GA, Goldstein J, Polis A, et al. Efficacy and safety of rizatriptan versus standard care during long-term treatment for migraine. Rizatriptan Multicenter Study Groups. Headache 1998;38:764-71
   PubMed Web of Science ®Google Scholar
• Donaldson C, Boers PM, Hoskin KL, et al. The role of 5-HT1B and 5-HT1D receptors in the selective inhibitory effect of naratriptan on trigeminovascular neurons. Neuropharmacology 2002;42:374-85
   PubMed Web of Science ®Google Scholar
• Jhee SS, Shiovitz T, Crawford AW, Cutler NR. Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review. Clin Pharmacokinet 2001;40:189-205
   PubMed Web of Science ®Google Scholar
• Havanka H, Dahlof C, Pop PH, et al. Efficacy of naratriptan tablets in the acute treatment of migraine: a dose-ranging study. Naratriptan S2WB2004 Study Group. Clin Ther 2000;22:970-80
   PubMed Web of Science ®Google Scholar
• Chen LC, Ashcroft DM. Meta-analysis examining the efficacy and safety of almotriptan in the acute treatment of migraine. Headache 2007;47:1169-77
   PubMed Web of Science ®Google Scholar
• Dodick DW. Oral almotriptan in the treatment of migraine: safety and tolerability. Headache 2001;41:449-55
   PubMed Web of Science ®Google Scholar
• Sanford M. Frovatriptan: a review of its use in the acute treatment of migraine. CNS Drugs 2012;26:791-811
   PubMed Web of Science ®Google Scholar
• Johnston MM, Rapoport AM. Triptans for the management of migraine. Drugs 2010;70:1505-18
   PubMed Web of Science ®Google Scholar
• Negro A, Lionetto L, Casolla B, et al. Pharmacokinetic evaluation of frovatriptan. Expert Opin Drug Metab Toxicol 2011;7:1449-58
   PubMed Web of Science ®Google Scholar
• Ryan R, Geraud G, Goldstein J, et al. Clinical efficacy of frovatriptan: placebo-controlled studies. Headache 2002;42(Suppl 2):S84-92
   PubMed Web of Science ®Google Scholar
• Rapoport A, Ryan R, Goldstein J, Keywood C. Dose range-finding studies with frovatriptan in the acute treatment of migraine. Headache 2002;42(Suppl 2):S74-83
   PubMed Web of Science ®Google Scholar
• Law S, Derry S, Moore RA. Sumatriptan plus naproxen for acute migraine attacks in adults. Cochrane Database Syst Rev 2013;10:CD008541
   PubMedGoogle Scholar
• Mathew NT, Landy S, Stark S, et al. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. Headache 2009;49:971-82
   PubMed Web of Science ®Google Scholar
• Allais G, Tullo V, Cortelli P, et al. Efficacy of early vs. late use of frovatriptan combined with dexketoprofen vs. frovatriptan alone in the acute treatment of migraine attacks with or without aura. Neurol Sci 2014;35(Suppl 1):107-13
   PubMedGoogle Scholar
• Krymchantowski AV, Barbosa JS. Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: an open label pilot study. Cephalalgia 2002;22:309-12
   PubMed Web of Science ®Google Scholar
• Schoenen J, De Klippel N, Giurgea S, et al. Almotriptan and its combination with aceclofenac for migraine attacks: a study of efficacy and the influence of auto-evaluated brush allodynia. Cephalalgia 2008;28:1095-105
   PubMed Web of Science ®Google Scholar
• Tullo V, Valguarnera F, Barbanti P, et al. Comparison of frovatriptan plus dexketoprofen (25 mg or 37.5 mg) with frovatriptan alone in the treatment of migraine attacks with or without aura: a randomized study. Cephalalgia 2014;34:434-45
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Marcus DA. Sumatriptan: treatment across the full spectrum of migraine. Expert Opin Pharmacother 2013;14:1659-67
   PubMed Web of Science ®Google Scholar
• Sandrini G, Perrotta A, Tassorelli C, Nappi G. Eletriptan. Expert Opin Drug Metab Toxicol 2009;5:1587-98
   PubMed Web of Science ®Google Scholar
• Mathew NT, Hettiarachchi J, Alderman J. Tolerability and safety of eletriptan in the treatment of migraine: a comprehensive review. Headache 2003;43:962-74
   PubMed Web of Science ®Google Scholar
• The International 311CXO Long-ten Study Group, Group TICL-tS. The long-term tolerability and efficacy of oral zolmitriptan (Zomig, 311C90) in the acute treatment of migraine. An international study. Headache 1998;38:173-83
   PubMed Web of Science ®Google Scholar
• Klassen A, Elkind A, Asgharnejad M, et al. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. Naratriptan S2WA3001 Study Group. Headache 1997;37:640-5
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P. Optimal balance of efficacy and tolerability of oral triptans and telcagepant: a review and a clinical comment. J Headache Pain 2011;12:275-80
   PubMed Web of Science ®Google Scholar
• Wallasch TM. Frovatriptan in the practice of office-based neurologists/pain therapists: results of postmarketing surveillance study ALADIN. Adv Ther 2010;27:56-62
   PubMed Web of Science ®Google Scholar
• Cassina M, Di Gianantonio E, Toldo I, et al. Migraine therapy during pregnancy and lactation. Expert Opin Drug Saf 2010;9:937-48
   PubMed Web of Science ®Google Scholar
• Momma K, Hagiwara H, Konishi T. Constriction of fetal ductus arteriosus by non-steroidal anti-inflammatory drugs:study of additional 34 drugs. Prostaglandins 1984;28:527-36
   PubMed Web of Science ®Google Scholar
• Marchenko A, Etwel F, Olutunfese O, et al. Pregnancy outcome following prenatal exposure to triptan medications: a meta-analysis. Headache 2015. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Nezvalova-Henriksen K, Spigset O, Nordeng H. Triptan safety during pregnancy: a Norwegian population registry study. Eur J Epidemiol 2013;28:759-69
   PubMed Web of Science ®Google Scholar
• Hutchinson S, Marmura MJ, Calhoun A, et al. Use of common migraine treatments in breast-feeding women: a summary of recommendations. Headache 2013;53:614-27
   PubMed Web of Science ®Google Scholar
• Sachs HC, Committee On D. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. Pediatrics 2013;132:e796-809
   PubMed Web of Science ®Google Scholar
• Davanzo R, Bua J, Paloni G, Facchina G. Breastfeeding and migraine drugs. Eur J Clin Pharmacol 2014;70:1313-24
   PubMed Web of Science ®Google Scholar
• Shane JM, Naftolin F. Effect of ergonovine maleate on puerperal prolactin. Am J Obstet Gynecol 1974;120:129-31
   PubMed Web of Science ®Google Scholar
• Soldin OP, Dahlin J, O’Mara DM. Triptans in pregnancy. Ther Drug Monit 2008;30:5-9
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 2001;108:776-89
   PubMed Web of Science ®Google Scholar
• Kristoffersen ES, Lundqvist C. Medication-overuse headache: epidemiology, diagnosis and treatment. Ther Adv Drug Saf 2014;5:87-99
   PubMedGoogle Scholar
• Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013;33:629-808
   PubMed Web of Science ®Google Scholar
• Bigal ME, Lipton RB. Overuse of acute migraine medications and migraine chronification. Curr Pain Headache Rep 2009;13:301-7
   PubMed Web of Science ®Google Scholar
• Lipton RB, Serrano D, Nicholson RA, et al. Impact of NSAID and Triptan use on developing chronic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache 2013;53:1548-63
   PubMed Web of Science ®Google Scholar
• Meskunas CA, Tepper SJ, Rapoport AM, et al. Medications associated with probable medication overuse headache reported in a tertiary care headache center over a 15-year period. Headache 2006;46:766-72
   PubMed Web of Science ®Google Scholar
• Hagen K, Linde M, Steiner TJ, et al. Risk factors for medication-overuse headache: an 11-year follow-up study. The Nord-Trondelag Health Studies. Pain 2012;153:56-61
   PubMed Web of Science ®Google Scholar
• Lyngberg AC, Rasmussen BK, Jorgensen T, Jensen R. Secular changes in health care utilization and work absence for migraine and tension-type headache: a population based study. Eur J Epidemiol 2005;20:1007-14
   PubMed Web of Science ®Google Scholar
• Tuka B, Helyes Z, Markovics A, et al. Alterations in PACAP-38-like immunoreactivity in the plasma during ictal and interictal periods of migraine patients. Cephalalgia 2013;33:1085-95
   PubMed Web of Science ®Google Scholar
• Vecsei L, Szalardy L, Fulop F, Toldi J. Kynurenines in the CNS: recent advances and new questions. Nat Rev Drug Discov 2013;12:64-82
   PubMed Web of Science ®Google Scholar
• Vecsei L, Tuka B, Tajti J. Role of PACAP in migraine headaches. Brain 2014;137:650-1
   PubMed Web of Science ®Google Scholar
• Andersson PG, Hinge HH, Johansen O, et al. Double-blind study of naproxen vs placebo in the treatment of acute migraine attacks. Cephalalgia 1989;9:29-32
   PubMed Web of Science ®Google Scholar